Lung Cancer
News
Real-world data for immunotherapy-treated NSCLC found robust
Endpoints seen among patients treated with PD-1/PD-L1 inhibitors in real-world settings were consistent within data sets and similar to those...
News
Hurricanes delay RT, worsening survival of NSCLC
Patients undergoing definitive radiotherapy during a declaration of hurricane disaster had a 21-day longer radiation treatment duration and were...
News
Investigators target brain metastases in NSCLC
In a retrospective study of matched primary and metastases samples, PI3K signaling was associated with an increased risk of brain metastases, and...
News
Immunotherapy-treated NSCLC: Adverse impact of steroids driven by palliative indications
A new analysis suggests use of steroids for cancer-related palliation in patients with poor prognosis largely explains their association with...
News
Neoadjuvant-adjuvant erlotinib shows promise in locally advanced NSCLC
The EMERGING trial failed to meet its primary endpoint of higher OR but did meet the secondary endpoint of longer PFS.
Conference Coverage
Adding ipilimumab to nivolumab provides no benefit in SCC trial
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
News
FDA approves NovoTTF-100L System for advanced mesothelioma
The System delivers electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division and can be prescribed only by a...
News
Local consolidative therapy shows benefit in oligometastatic NSCLC
Patients treated with local consolidative therapy had a median overall survival of 41.2 months, compared with 17.0 months among patients treated...
News
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?
One common EGFR tyrosine kinase inhibitor–sensitizing allele may be associated with similar benefit versus EGFR wild-type lung tumors, analysis...
